Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The Association of Directors of Anatomic and Surgical Pathology

Department of Pathology, Stanford University, Stanford, CA 94025, USA.
Human pathology (Impact Factor: 2.81). 05/2009; 40(4):456-63. DOI: 10.1016/j.humpath.2008.12.004
Source: PubMed

ABSTRACT A checklist based approach to reporting the relevant pathologic details of renal cell carcinoma resection specimens improves the completeness of the report. Karyotypic evaluation of renal neoplasms has refined but also complicated their classification. The number of diagnostic possibilities has increased and the importance of distinguishing different tumor types has been underscored by dramatic variation in prognosis and the development of targeted therapies for specific subtypes. The increasing number of recognized renal neoplasms has implications for handling renal resection specimens. Furthermore, the prognostic significance of other features of renal neoplasms related to grade and stage has been demonstrated. This guideline for the handling of renal resection specimens will focus on problem areas in the evolving practice of diagnosis, grading, and staging of renal neoplasms. The accompanying checklist will serve to ensure that all necessary details of the renal resection specimen are included in the surgical pathology report.


Available from: James D Brooks, May 27, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The last few years have brought advances in the understanding of the molecular biology of metastatic clear cell renal cell carcinoma (RCC). Both preclinical research and clinical trials brought together results from the latest advancements in RCC diagnostic and staging. Understanding of the complex molecular alterations involved in the development and progression of RCC enables development of immunohistochemical and genetic diagnostic tools and is also opening the doors for experimental targeted therapies. At the same time, improvements of medical and molecular imaging improves the sensitivity and specificity of metastatic disease diagnosis. Moreover, independent validation of molecular profiles across high-throughput platforms, methods, laboratories and cancer populations has recently been successfully performed in RCC. Generation of informative, clinical diagnostic tools is likely to contribute to development of novel personalized diagnostic and treatment protocols and ensure prolonged survival of RCC patient in the near future.
    Future Oncology 05/2014; 10(6):1095-111. DOI:10.2217/fon.13.258 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The renal sub Committee of the CCAFU established guidelines for diagnosis, treatment, evaluation and standard of care for renal cell carcinoma. 2010 Guidelines were updated based on systematic literature search performed by the sub-Committee in Medline and PubMed databases to evaluate references, levels of evidence and grade of recommendation. Multiphasic CT is the standard imaging technique for renal tumors diagnosis. Percutaneous renal biopsies are increasingly important for the management of localized RCC. Partial Nephrectomy is the first option when technically feasible for cT1 tumours. Open surgery remains the standard approach for locally advanced RCCs. New drugs are available for the treatment of metastatic RCC while the role of nephrectomy needs to be established by the Carmena trial. Conservative and mini-invasive therapies are increasingly important for the management of localized RCC. Therapeutic armamentarium continues to increase in mRCC.
    Progrès en Urologie 11/2013; 23 Suppl 2:S177-204. DOI:10.1016/S1166-7087(13)70055-1 · 0.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal cell carcinoma (RCC) is diagnosed in over 65,000 Americans annually, and earlier detection and advances in surgical techniques have resulted in improved oncological outcomes. Given that diabetes and hypertension are independent risk factors for the development of RCC, it is not surprising that diabetic nephropathy or hypertensive nephrosclerosis are commonly encountered in these patients. Data support that at least one third of the 300,000 kidney cancer survivors in the United States have or will develop CKD; however, the effect of CKD in this clinical setting has largely evaded the attention of the medical community. It is likely that CKD which develops from postsurgical therapy for RCC may limit long-term outcomes by increasing the risk for cardiovascular morbidity and mortality. To further improve the clinical outcomes for kidney cancer patients, better recognition and management of CKD, which requires coordination among urologists, pathologists, and nephrologists, will be essential.
    Advances in chronic kidney disease 01/2014; 21(1):91-5. DOI:10.1053/j.ackd.2013.09.003 · 1.94 Impact Factor